Skip to main content
. 2014 Jun;26(3):323–330. doi: 10.3978/j.issn.1000-9604.2014.06.07

Figure 2.

Figure 2

ERCC1 expression and the survival of patients with gastric cancer. (A) ERCC1 expression and overall survival of patients with gastric cancer (P=0.455); (B) impact of cisplatin combined with fluorouracil chemotherapy on survival of ERCC1-positive patients (P=0.162); (C) impact of cisplatin combined with fluorouracil chemotherapy on survival of ERCC1-negative patients (P=0.019); (D) ERCC1 expression and survival of patients with gastric cancer without postoperative adjuvant chemotherapy (P=0.183). ERCC1, excision repair cross-complementation group 1.